Vontobel Holding Ltd. Has $12.06 Million Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Vontobel Holding Ltd. raised its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 5.5% during the second quarter, according to its most recent filing with the SEC. The firm owned 719,676 shares of the company's stock after purchasing an additional 37,455 shares during the period. Vontobel Holding Ltd. owned 0.06% of Teva Pharmaceutical Industries worth $12,062,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of TEVA. Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 197,885.2% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock valued at $338,989,000 after acquiring an additional 22,044,407 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of Teva Pharmaceutical Industries by 472.8% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 6,283,688 shares of the company's stock valued at $96,078,000 after acquiring an additional 5,186,592 shares during the period. Nuveen LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 1st quarter valued at $40,827,000. Assenagon Asset Management S.A. lifted its position in shares of Teva Pharmaceutical Industries by 41.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 8,445,992 shares of the company's stock valued at $141,555,000 after acquiring an additional 2,462,064 shares during the period. Finally, Ion Asset Management Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 6.5% during the 1st quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company's stock valued at $599,945,000 after acquiring an additional 2,383,500 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. UBS Group boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a "buy" rating in a research report on Wednesday, September 24th. Weiss Ratings restated a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company an "overweight" rating in a research note on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $25.57.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $20.05 on Friday. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. The firm has a market cap of $23.00 billion, a price-to-earnings ratio of -125.31, a PEG ratio of 1.17 and a beta of 0.71. The company has a fifty day moving average price of $18.42 and a 200-day moving average price of $16.92.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.02. The firm had revenue of $4.18 billion during the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business's revenue was up .3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Insider Activity

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the sale, the insider owned 6,774 shares of the company's stock, valued at approximately $102,693.84. The trade was a 47.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. Insiders own 0.49% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.